Poll

Poll: In an RCC patient with a 4- to 7-cm tumor and no metastasis, which one of the following treatments would you recommend?

Microwave ablation
Partial nephrectomy
Radical nephrectomy
Other
Depends on patient preference
Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Study data point to gender disparities in oncology research citations
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Related Content
3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
May 19th 2025

Patient selection for cytoreductive nephrectomy in 2025

Daniel D. Shapiro, MD, FACS E. Jason Abel, MD, FACS
"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
April 3rd 2025

Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

Mehmet Asim Bilen, MD Hannah Clarke
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
April 2nd 2025

The importance of federal funding in cancer research: A call to action

Michael S. Cookson, MD, MMHC, FACS
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
FDA updates in urology: March 2025
April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
Subcutaneous nivolumab under review in EU for solid tumors
March 31st 2025

Subcutaneous nivolumab under review in EU for solid tumors

Hannah Clarke
The European Commission must issue a decision on the application on or by June 2, 2025.
© 2025 MJH Life Sciences

All rights reserved.